Patents Assigned to The Government of the United States of America as represented by the Secretary of the Department of
  • Patent number: 10724007
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 28, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
  • Patent number: 10703708
    Abstract: The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: July 7, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: François Guerard, Jean-François Gestin, Martin W. Brechbiel, Yong-Sok Lee
  • Patent number: 10695414
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 30, 2020
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara Carthel Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Patent number: 10669591
    Abstract: A process for detecting Haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a Haemophilus influenzae nucleotide sequence and measuring the amplification product to detect Haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay. Also provided are reagents and methods for detecting and distinguishing Haemophilus influenzae from other infectious agents. A kit is provided for detecting and quantifying Haemophilus influenzae in a sample.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: June 2, 2020
    Assignee: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Jennifer Thomas, Xin Wang, Cynthia Hatcher, Raydel Anderson, Mary Jordan Theodore, Leonard W. Mayer
  • Publication number: 20200149069
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Application
    Filed: January 24, 2020
    Publication date: May 14, 2020
    Applicants: The Government of the United States of America as Represented by the Secretary of the Department of, GlaxoSmithKline Biologicals SA
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 10584355
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 10, 2020
    Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 10568956
    Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 25, 2020
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
  • Patent number: 10557118
    Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: February 11, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
  • Patent number: 10494435
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 3, 2019
    Assignee: The Government of the United States America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • Patent number: 10485879
    Abstract: A fusion molecule is provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety. The targeting polypeptide and the nucleic acid binding moiety include specific the amino acid sequences. A fusion molecule is also provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety adapted to bind a double-stranded RNA or to a small hairpin RNA. The targeting polypeptide being CCL27 or CCL11 or a fragment thereof.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: November 26, 2019
    Assignees: Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health
    Inventors: Bira Arya, Michael R. Simon
  • Patent number: 10449231
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: October 22, 2019
    Assignees: TAKEDA VACCINES, INC., The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
  • Patent number: 10400031
    Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: September 3, 2019
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Todd G. Smith, Xianfu Wu
  • Publication number: 20190262449
    Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 29, 2019
    Applicant: The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Michail V. Sitkovsky, Akio Ohta
  • Publication number: 20180244728
    Abstract: This application is directed generally to minicircle DNA vectors for the vaccination of foot-and-mouth disease (FMD). The transgene expression cassette in the minicircle DNA vector includes: a eukaryotic translation initiation nucleotide sequence, a mutant nucleotide sequence that encodes a foot-and-mouth disease virus (FMDV) capsid polyprotein precursor that contains at least one mutation to eliminate a restriction enzyme recognition site, a nucleotide sequence that encodes a protease that cleaves the FMDV capsid polyprotein precursor into a plurality of FMDV capsid proteins and a translational regulatory element to regulate the expression of the protease. The minicircle DNA vectors can be transfected directly into the cell of a mammalian host. When transfected into the mammalian host cell, virus-like particles can be produced intrinsically to stimulate the mammalian host's immune system to develop adaptive immunity toward foot-and-mouth disease.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 30, 2018
    Applicant: The Government of the United States of America, as Represented by the Secretary, Department of
    Inventors: Michael Puckette, Max Rasmussen, John Neilan
  • Publication number: 20180147269
    Abstract: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 31, 2018
    Applicants: The Government of the United States of America as represented by the Secretary of the Department of, Fundaçao Oswaldo Cruz (FIOCRUZ)
    Inventors: Jesus G. Valenzuela, Jose M.C. Ribeiro, Aldina Barral, Manoel Barral Netto, Claudia I. Brodskyn, Regis Gomes
  • Patent number: 9864026
    Abstract: An implantable parametric circuit enables local signal amplification and wireless transmission of RF signals in connection with magnetic resonance imaging systems. The parametric circuit detects RF signal detected during magnetic resonance imaging procedure, amplifies the detected RF signal, and transmits the amplified RF signal in a wireless manner to an external pick-up coil. The parametric amplifier is also configured to use another RF signal generated by an external source as the primary power source. As a result, implanted or catheter coils could be used as a wireless signal transducer without the need for a battery or a power connection.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: January 9, 2018
    Assignee: The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Chunqi Qian, Joe Murphy-Boesch, Alan Koretsky, Stephen John Dodd
  • Publication number: 20170318132
    Abstract: An interface device for provisioning Internet Protocol (IP) communications to be established for base station equipment that employ proprietary device specific protocols. A fixed station interface (FSI) translates between a V.24 High-Level-Data-Link Control (HDLC) protocols used for external data connections on base station equipment to a Voice-Over-Internet-Protocol (VOIP) open-standard protocol. Upon being deployed in First Responder communications networks (that use legacy base station equipment), the FSI provisions for the retention of existing installed base station equipment while providing a low cost solution to support VOIP communications interconnectivity and reliability, thereby enhancing the effectiveness and safety of the First Responder systems.
    Type: Application
    Filed: September 21, 2015
    Publication date: November 2, 2017
    Applicant: The Government of the United States of America, as Represented by the Secretary, Department of Homel
    Inventor: Richard Brockway
  • Patent number: 9803251
    Abstract: Disclosed herein are methods of detecting influenza virus in a sample from a subject. In some embodiments, the disclosed methods include contacting a sample with at least one primer 10-40 nucleotides in length wherein the at least one primer is capable of hybridizing to an influenza virus polymerase basic protein 1 (PB1) nucleic acid at least 70% identical to the nucleic acid sequence set forth as any one of SEQ ID NOs: 1-3, amplifying the PB1 nucleic acid or a portion thereof to produce an amplified PB1 nucleic acid, and detecting the amplified PB1 nucleic acid, wherein presence of the amplified PB1 nucleic acid indicates presence of influenza virus in the sample from the subject. In some examples, the primers comprise or consist of the nucleic acid sequence set forth as one of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 10.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: October 31, 2017
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventor: Suxiang Tong
  • Publication number: 20170275625
    Abstract: Described herein are methods and compositions for the treatment of colon cancers.
    Type: Application
    Filed: April 11, 2017
    Publication date: September 28, 2017
    Applicants: The Ohio State University Research Foundation, The Government of the United States of America, as represented by the Secretary of the Department of
    Inventors: Carlo M. Croce, Curtis C. Harris, Aaron J. Schetter
  • Publication number: 20170211066
    Abstract: Methods and compositions for the treatment of prostate associated disorders are disclosed.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Applicants: The Ohio State University Research Foundation, The Government of the United States of America, as represented by the Secretary of the Department of
    Inventors: Carlo M. Croce, Stefan Ambs